For example, astragaloside IV from A. membranaceus (Huangqi) (Song et al., 2018; Wang et al., 2020; Su et al., 2023), tanshinone IIA from S. miltiorrhiza (Danshen) (Chai et al., 2023; Song et al., 2021; Xu et al., 2024), and ginsenosides from P. ginseng (Renshen) (Yanna et al., 2022; Jang et al., 2023; Li et al., 2025) have been reported to inhibit NF-κB signaling and reduce inflammatory damage in various cardiovascular disease models. Here, NFKB1 is linked to cardiovascular disorder.